dr. reddy's labs glp-1 receptor agonist weight management diabetes treatments With the launch of our oral semaglutide biosimilar, Obeda® tablets, we are broadening our GLP‑1 portfolio to offer more choice and flexibility for patients. Oral semaglutide, as a convenient and flexible option GLP‑1 Therapies: Transforming Obesity Treatment
Description
Messineo L et al
In a meta-analysis of 38 randomized controlled trials (2199 children and adolescents, mean age 13.7 years
Trail registration Study registered in clinicaltrials.org with the identifier NCT05535322
[DOI] [PubMed] [Google Scholar] 97
42) In SUSTAIN-6, patients treated with semaglutide had a lower risk of developing or worsening nephropathy, but a higher risk of complications from diabetic retinopathy than those receiving placebo (40)
She lost weight
